pharma news
Oct 20, 2026
Nouscom Announces €120 Million Series D Funding and Upcoming Presentation of Long-Term Lynch Syndrome Clinical Data at ESMO; Viatris Announces FDA Approval of RYZUMVI for Presbyopia; Lilly’s Omvoh Meets Clinical Remission Endpoint in Children with Ulcerative Colitis; Estuary Biotherapeutics Debuts with $103 Million in Funding to Tackle Kidney Disease; Roche’s Enspryng Receives FDA Approval as a First-in-Class IL-6R Inhibitor for Thyroid Eye Disease
Nouscom Secures Major Series D Funding and Prepares to Share Long-Term Clinical Findings in Lynch Syndrome Carriers at ESMO Nouscom has announced the completion of an oversubscribed €120 million ($135 million) Series D financing round. The investment was co-led by M Ventures and Revelation Partners, with partici...
Read More...
Oct 13, 2026
Efzimfotase Alfa Achieves 17.05-Metre Numerical Improvement Over Placebo in Six-Minute Walk Test; Asahi Kasei Therapeutics Announces First Patient Dosed in Phase 2a Study of AIC468 for BK Virus; Teva’s WELTRUZA Gains FDA Approval for Once-Monthly Treatment of Adult Schizophrenia; Innovent’s SYCUME Meets Primary Endpoint in Phase 3 Inactive Thyroid Eye Disease Trial; Zealand Pharma’s Petrelintide Delivers Positive Topline Results in Phase 2 ZUPREME-2 Trial
Efzimfotase Alfa Shows Numerical Improvement in Six-Minute Walk Distance Versus Placebo in HICKORY Phase III Trial Results from the HICKORY Phase III trial indicated that efzimfotase alfa (ALXN1850), an investigational enzyme replacement therapy, did not achieve statistical significance for the primary endpoint ...
Read More...
Oct 06, 2026
Vaxcyte Announces Positive Phase 3 Topline Data for VAX-31 from OPUS-1 Trial; CSL and Alentis Partner to Advance Lixudebart for Rare Renal and Hepatic Diseases; Pfizer Announces Positive Repigmentation Results for LITFULO in Nonsegmental Vitiligo; AstraZeneca Completes Equity Investment in Summit Therapeutics; Lilly’s Jaypirca Receives FDA Approval Expansion for Certain Patients with Untreated CLL/SLL; Merck’s Tulisokibart Delivers Positive Phase 2b Results in Moderate-to-Severe Hidradenitis Suppurativa
Vaxcyte Reports Successful Topline Outcomes from Pivotal Phase 3 OPUS-1 Study of VAX-31 Vaxcyte, Inc. reported positive topline findings from OPUS-1, its pivotal Phase 3 trial in adults evaluating the safety, tolerability, and immunogenicity of VAX-31, the company’s next-generation 31-valent pneumococcal conjuga...
Read More...
Sep 29, 2026
Roche Announces Positive Interim Results for Sefaxersen in IgA Nephropathy; Lilly’s Olumiant Receives FDA Approval for Pediatric Patients With Severe Alopecia Areata; AbbVie’s JUVMO Receives U.S. FDA Approval for Parkinson’s Disease; Biologics License Application for Ifinatamab Deruxtecan Withdrawn in Extensive-Stage Small Cell Lung Cancer; Mirum Pharmaceuticals Reports Primary Endpoint Success in Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus
Roche Reports Positive Interim Data Showing Sefaxersen Significantly Reduces Proteinuria in IgA Nephropathy Roche announced positive prespecified interim results from the ongoing Phase III IMAgINATION study evaluating investigational sefaxersen in adults with primary IgA nephropathy (IgAN). The trial achieved it...
Read More...
Sep 22, 2026
Novo’s CagriSema Shows Greater Weight Loss Than Tirzepatide in REIMAGINE 5 Trial; Telix and ITM Partner to Build a Radiopharmaceutical Powerhouse; Beacon Therapeutics Reveals Positive Topline Findings from VISTA Trial of Laru-zova for XLRP; FDA Clears Inluriyo in Combination with Verzenio for Adults with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer; IntraBio Announces FDA Approval of AQNEURSA for Ataxia-Telangiectasia
Novo’s CagriSema Demonstrates Superior Weight Loss Over Tirzepatide in REIMAGINE 5 Novo Nordisk announced topline results from the Phase 3 REIMAGINE 5 and REDEFINE 9 trials evaluating once-weekly CagriSema (cagrilintide and semaglutide), an investigational therapy and the company’s next-generation approach to we...
Read More...
Sep 15, 2026
TAGRISSO Delivers Landmark Eight-Year Survival Outcomes in Early-Stage EGFR-Mutated Lung Cancer; Scholar Rock Receives FDA Approval for ISEMBYLD; Pharming’s Joenja Receives FDA Approval as First U.S. Treatment for Children With APDS; AbbVie Reports Positive Phase 3 Results for Atogepant in Menstrual Migraine; Rezera’s Ruvonoflast Delivers Positive Inflammation Results with Favorable Safety in RESOLVE-1
TAGRISSO Demonstrates Eight-Year Landmark Survival Benefit for Patients with Early-Stage EGFR-Mutated Lung Cancer Updated exploratory findings from the Phase III ADAURA trial demonstrated that AstraZeneca’s Tagrisso (osimertinib) continued to provide a sustained and clinically meaningful overall survival (OS) be...
Read More...
Sep 08, 2026
Novo Nordisk’s STEP Young Phase 3 Results Highlight Semaglutide’s Potential in Pediatric Obesity; Clover Reports Positive Phase 2 Clinical Findings for RSV + hMPV ± PIV3 Vaccine Candidates; Novartis Reveals Topline Results From Phase III Lp(a)HORIZON Trial of Pelacarsen; US Approves Etcamah Plus CDK4/6 Inhibitor for 1st-Line Advanced HR-Positive Breast Cancer; ZANVASTRO Wins FDA Approval as a First-of-Its-Kind Disease-Modifying Treatment for Alexander Disease
Novo Nordisk’s STEP Young Phase 3 Study Shows Semaglutide Reduced Obesity Classification in 40.4% of Children Novo Nordisk announced the initial results from the STEP Young Phase 3 trial, which evaluated once-weekly semaglutide in combination with lifestyle modifications, including a reduced-calorie diet and inc...
Read More...
Sep 01, 2026
Takeda’s MIMRYLO Wins U.S. FDA Approval for Polycythemia Vera; Lilly’s Mounjaro Gains FDA Approval for Cardiovascular Risk Reduction in Type 2 Diabetes; Teva Expands Neuroscience Portfolio Through Proposed Acquisition; BioNTech Ends Phase 2 Study of Autogene Cevumeran in Colorectal Cancer; AusperBio Secures $120 Million Series C to Advance AHB-137 and Next-Generation Hepatitis B Therapies
Takeda Gains FDA Approval for MIMRYLO Takeda announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for MIMRYLO™ (rusfertide) to treat erythrocytosis in adults with polycythemia vera (PV), a type of blood cancer. MIMRYLO is a first-in-class hepcidin mimetic develop...
Read More...
Aug 25, 2026
US FDA Grants Priority Review to Jemperli for dMMR/MSI-H Locally Advanced Rectal Cancer; Amylyx’s Avexitide Achieves Positive Topline Results in Phase 3 LUCIDITY Study; Ultragenyx Marks Major Milestone as FDA Approves GENGLYCOS for GSDIa; Pasatru Receives FDA Approval for Fibrodysplasia Ossificans Progressiva; Merck and Moderna’s Intismeran Autogene Plus KEYTRUDA Delivers Positive Phase 3 Results in Resected Melanoma
GSK’s Jemperli Granted FDA Priority Review for dMMR/MSI-H Locally Advanced Rectal Cancer GSK plc announced that the US Food and Drug Administration (FDA) has accepted its supplemental Biologics License Application (sBLA) for priority review of Jemperli (dostarlimab) as a potential treatment for patients with pre...
Read More...
Aug 18, 2026
AstraZeneca Discontinues Phase III eVOLVE-Lung02 Trial of Volrustomig in Metastatic NSCLC; argenx Announces Favorable Topline Results from Phase 3 ALKIVIA Study of Efgartigimod; Bristol Myers Squibb’s ZENBEXUS Receives U.S. FDA Accelerated Approval in Combination with Daratumumab and Dexamethasone for Multiple Myeloma; Zealand Pharma Secures USD 100 Million in Royalty Financing Through Agreement with Royalty Pharma for Rusfertide; PTC Advances Rare Disease Strategy with Acquisition of ST-920 Fabry Disease Program
AstraZeneca Ends eVOLVE-Lung02 Phase III Trial Evaluating Volrustomig Plus Chemotherapy AstraZeneca has decided to discontinue the Phase III eVOLVE-Lung02 trial, which was assessing volrustomig in combination with chemotherapy as a first-line treatment for patients with metastatic non-small cell lung cancer (mNS...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
